Naloxone and compounded pharmaceuticals
Closed Special Notice Posted
- Solicitation number
- W81K0022Q0012
- Agency
- Medical Command Department of the Army, Department of Defense
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Jbsa Ft Sam Houston, Texas 78234, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Special Notice announces the Regional Health Contracting Office-Central's intent to award a sole source contract to Wells Pharma of Houston, LLC for the procurement of various compounded pharmaceuticals. The publishing agency is the Department of the Army Medical Command.
The Special Notice provides contractors with information regarding a forthcoming sole source contract award for naloxone, ketamine, and norepinephrine pharmaceutical products that meet specified characteristics such as concentration, packaging, and minimum beyond use dates. Interested parties are instructed that the notice is not a solicitation but submissions will be considered for future requirements. The opportunity is set aside for total small businesses and the primary NAICS code is 325412 with a size standard of 1,250 employees. The Special Notice includes key deadlines of December 23, 2021 for intent to award and submission of capability statements for future consideration.
Notice text
Regional Health Contracting Office-Central, Joint Base San Antonio-Fort Sam Houston, Texas intends to award a sole source contract to Wells Pharma of Houston, LLC. for Naloxone and compounded pharmaceuticals. Naloxone and compounded pharmaceuticals must meet the below salient characteristics:
Naloxone 1mg/mL 2mL Oral Syringe
Will contain a solution of Naloxone 1mg/ml packaged in 2mL oral syringe
Will be packaged in an oral syringe with a tamper evident cap and without a luer lock tip
Will be labeled for oral use only
Must have a Beyond Use Date of no less than 30 days
Ketamine 10mg/mL in Normal Saline 5mL in 10mL OR Syringe
Will contain ketamine 10mg/mL mixed with Normal Saline 5mL packaged in a 10mL OR syringe
Will have a label affixed to each syringe specifying the contents
Must have a Beyond Use Date of no less than 30 days
Ketamine 10mg/mL in Normal Saline 10mL in 10mL OR Syringe
Will contain ketamine 10mg/mL mixed with Normal Saline 10mL packaged in a 10mL OR syringe
Will have a label affixed to each syringe specifying the contents
Must have a Beyond Use Date of no less than 30 days
Norepinephrine 4mg in D5W 250mL bag
Will contain norepinephrine 4mg added to 250mL bag of dextrose 5% in water
Will have a label affixed to each bag specifying the contents
Must have a Beyond Use Date of no less than 30 day
Norepinephrine 8mg in D5W 250mL bag
Will contain norepinephrine 8mg added to 250mL bag of dextrose 5% in water
Will have a label affixed to each bag specifying the contents
Must have a Beyond Use Date of no less than 30 days
Award will be made on or about 23 December 2021. The primary NAICS code for the requirement 325412 with a size standard of 1,250 employees. This notice is neither a request for quotes nor a solicitation of offers; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency for future requirements.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Naloxone and compounded pharmaceuticals | Special Notice | |
| Naloxone and compounded pharmaceuticals | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity